BridgeBio Pharma, Inc. Income Statement
BBIO / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
BridgeBio Pharma, Inc. reported $502M in revenue and $733M in net loss for FY2025. Revenue has grown at a 52.1% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $69.7M | $77.6M | $40.6M | $8.2M | $40.6M | - | - |
| Cost of Revenue | $21.0M | $3.9M | $3.1M | $3.4M | $2.7M | - | - | - | - |
| SG&A Expense | $531.2M | $288.9M | $192.2M | $143.2M | $94.4M | $145.7M | $94.4M | $43.6M | $13.3M |
| R&D Expense | $452.0M | $506.5M | $451.0M | $399.5M | $209.9M | $337.0M | $209.9M | $140.1M | $30.6M |
| Operating Income | -$523.4M | -$593.0M | -$576.6M | -$512.2M | -$266.2M | -$474.5M | -$266.2M | -$183.7M | -$43.9M |
| Interest Expense | - | $34.3M | $46.8M | $80.4M | $8.8M | $36.7M | $8.8M | $2.5M | $13.0K |
| Income Tax | $435.0K | $1.2M | - | $0 | - | - | - | - | - |
| Net Income | -$732.9M | -$543.3M | -$586.5M | -$484.7M | -$288.6M | -$505.5M | -$288.6M | -$169.5M | -$43.8M |
| EPS (Basic) | -$3.95 | -$3.26 | -$3.90 | -$3.80 | - | - | - | - | - |
| EPS (Diluted) | -$3.95 | -$3.26 | -$3.90 | -$3.80 | -$2.48 | -$2.12 | -$1.00 | - | - |
| Shares Outstanding | 190.0M | 175.1M | 150.6M | 147.3M | 122.8M | 123.7M | 92.1M | 61.8M | 30.6M |
| Operating Margin | -104.3% | -267.2% | -827.1% | -659.6% | -656.4% | -5752.0% | -656.4% | - | - |
| Profit Margin | -146.0% | -244.9% | -841.2% | -624.2% | -711.5% | -6127.9% | -711.5% | - | - |